The two companies have entered into a license agreement to develop and commercialize Calliditas’ leading drug candidate Nefecon in Greater China and Singapore for the chronic autoimmune kidney disease IgA Nephropathy (IgAN). Under the terms of the agreement, Calliditas will receive an initial upfront payment of 15M USD at signing of the agreement, as well … Continue reading Calliditas Therapeutics in agreement with Everest Medicines